If you have been reading about certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-18. Numbers and descriptions here follow the published literature rather than marketing material.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
As the result of a program designed to develop a padding concept to improve crash protection for airplane passengers, Ames Research Center developed what is now called memory foam. Fagerdala World Foams managed to produce a mass-produced version in 1991, creating what they call "TEMPUR Foam". Memory foam has been incorporated into mattresses, pillows, military and civilian aircraft, automobiles and motorcycles, sports safety equipment, amusement park rides and arenas, horseback saddles, archery targets, furniture, and human and animal prostheses. Its high-energy absorption and soft characteristics offer protection and comfort. TEMPUR Foam was inducted into the Space Foundation Space Technology Hall of Fame in 1998.
== Further reading == Allen, Jeannie (6 September 2001). Ultraviolet Radiation: How it Affects Life on Earth. Earth Observatory. NASA, USA. Hockberger, Philip E. (2002). "A History of Ultraviolet Photobiology for Humans, Animals and Microorganisms". Photochemistry and Photobiology. 76 (6): 561–569. doi:10.1562/0031-8655(2002)0760561AHOUPF2.0.CO2. PMID 12511035. S2CID 222100404. Hu, S; Ma, F; Collado-Mesa, F; Kirsner, R. S. (July 2004). "UV radiation, latitude, and melanoma in US Hispanics and blacks". Arch. Dermatol. 140 (7): 819–824. doi:10.1001/archderm.140.7.819. PMID 15262692. Strauss, CEM; Funk, DJ (1991). "Broadly tunable difference-frequency generation of VUV using two-photon resonances in H2 and Kr". Optics Letters. 16 (15): 1192–4. Bibcode:1991OptL...16.1192S. doi:10.1364/ol.16.001192. PMID 19776917.
=== Sportspeople === Cyclist and Olympic gold medalist Anna Meares said "Unfair, unsafe – I just don't think this is the right way to go about sport." Cyclist Joseph M. Papp, suspended for doping in 2006, referred to a 1988 Weekend Update skit, saying: "I don't think you'd actually see guys tearing their arms off ... A doping free-for-all just invites the most ambitious person to be the most reckless person, and to take the most drugs possible without literally killing themselves." Badminton player Susan Egelstaff stated, "It cannot, and will not work. The danger is massive." Swimmer and Olympic gold medalist Leisel Jones stated that while she would not participate herself due to the risks, she'd be interested in how fast people could get with doping, saying: "If this clears out people who ... are doing illegal things in sport, if that clears them out our clean sport, that would be wonderful." Swimmer and Olympic gold medalist Libby Trickett said it was understandable TEG would attract fascination and interest, and that "I really, really, really hope that it's done under medical supervision because that's the only way I can kind of justify in my head something like this to go ahead." Olympic swimmer Mark Foster expressed similar views, noting also that money has attraction.
Sources: en.wikipedia.org
In general, primary databases have the fewest total protein interactions recorded as they do not integrate data from multiple other databases, while prediction databases have the most because they include other forms of evidence in addition to experimental. For example, the primary database IntAct has 572,063 interactions, the meta-database APID has 678,000 interactions, and the predictive database STRING has 25,914,693 interactions. However, some of the interactions in the STRING database are only predicted by computational methods such as Genomic Context and not experimentally verified.
MH+(H2O)m → MH+ + mH2O If the mobile phase contains solvents with a higher proton affinity than water, proton-transfer reactions take place that lead to protonated the solvent with higher proton affinity. For example, when methanol solvent is present, the cluster solvent ions would be CH3OH2+(H2O)n(CH3OH)m. Fragmentation does not normally occur inside the APCI source. If a fragment ion of a sample is observed, thermal degradation has taken place by the heated nebulizer interface, followed by the ionization of the decomposition products. In a major distinction from chemical ionization, the electrons needed for the primary ionization are not produced by a heated filament, as a heated filament cannot be used under atmospheric pressure conditions. Instead, the ionization must occur using either corona discharges or β- particle emitters, which are both electron sources capable of handling the presence of corrosive or oxidizing gases.
== Activity and Specificity == In common with most enzymes in family C1, caricain accepts hydrophobic amino acid residues in both S2 and S3. However, other residues are also accommodated in these subsites, including proline in S2, and lysine in S3. The specificities of three cysteine endopeptidases from papaya latex were found to be very similar. Caricain and chymopapain appeared to prefer an aliphatic to a hydrophobic residue at P2. The similarity in specificity of caricain and chymopapain was demonstrated by the fact that, of 44 peptide bonds in manatee hemoglobin cleaved by caricain, 29 were also cleaved by chymopapain. An earlier study had highlighted the similarity in specificity of caricain, chymopapain and papain. All seven bonds of the oxidized B chain of insulin that were hydrolyzed by caricain were also cleaved by papain, and six were hydrolyzed by chymopapain. Caricain can be assayed with Bz-ArgkNHPhNO2, kcat/Km being 187 M21 s21 at pH 6.8 and 40˚C. More sensitive substrates may employ a fluorometric leaving group, kcat/Km for the hydrolysis of Z-Phe-ArgkNHMec being 1.06 3 106 M21 s21 (pH 6.8, 40˚C). The enzyme exhibits a broad pH-activity profile, with the optimum near 7.0. About half-maximal activity is still achieved at pH values of about 5.3 and 8.3, and the profile is reported to be governed by at least three ionizing groups. The active-site sulfur requires reduction for catalytic competence, and this is best achieved by the inclusion of low millimolar concentrations of cysteine in assay buffers.
ADME is the four-letter abbreviation (acronym) for absorption, distribution, metabolism, and excretion, and is mainly used in fields such as pharmacokinetics and pharmacology. The four letters stand for descriptors quantifying how a given drug interacts within the body over time. The term ADME was first introduced in the 1960s, and has become a standard term widely used in scientific literature, teaching, drug regulations, and clinical practice. ADME describes the disposition of a pharmaceutical compound within an organism. The four criteria all influence the drug levels and kinetics of drug exposure to the tissues and hence influence the performance and pharmacological activity of the compound as a drug. Sometimes liberation and/or toxicity are also considered, yielding LADME, ADMET, or LADMET.
Sources: en.wikipedia.org
As well as alpha and beta chains present in hemoglobin, about 3% of adult hemoglobin is made of alpha and delta globin chains. Just as with beta thalassemia, mutations that affect the ability of this gene to produce delta chains can occur.
A ligand binding assay (LBA) is an assay, or an analytic procedure, which relies on the binding of ligand molecules to receptors, antibodies or other macromolecules. A detection method is used to determine the presence and amount of the ligand-receptor complexes formed, and this is usually determined electrochemically or through a fluorescence detection method. This type of analytic test can be used to test for the presence of target molecules in a sample that are known to bind to the receptor. There are numerous types of ligand binding assays, both radioactive and non-radioactive. Some newer types are called "mix-and-measure" assays because they require fewer steps to complete, for example foregoing the removal of unbound reagents. Ligand binding assays are used primarily in pharmacology for various demands. Specifically, despite the human body's endogenous receptors, hormones, and other neurotransmitters, pharmacologists utilize assays in order to create drugs that are selective, or mimic, the endogenously found cellular components. On the other hand, such techniques are also available to create receptor antagonists in order to prevent further cascades. Such advances provide researchers with the ability not only to quantify hormones and hormone receptors, but also to contribute important pharmacological information in drug development and treatment plans.
=== Sources === Abdelal, Rawi; Bros, Aurélie (2020). "The End of Transatlanticism?: How Sanctions Are Dividing the West". Horizons: Journal of International Relations and Sustainable Development. 16 (16). Center for International Relations and Sustainable Development: 114–135. JSTOR 48573754. Davis, Stuart; Ness, Immanuel, eds. (2023). Sanctions as War: Anti-Imperialist Perspectives on American Geo-Economic Strategy. Haymarket Books. ISBN 978-1-64259-812-4. OCLC 1345216431. Beal, Tim. "2: Sanctions as Instrument of Coercion: Characteristics, Limitations, and Consequences". In Davis (ed) 2023, pp. 27–50. Bridenthal, Renate. "19: Blowback to US Sanctions Policy". In Davis (ed) 2023, pp. 323–332. Davis, Stuart. "4: Economic Sanctions, Communications Infrastructures, and the Destruction of Communicative Sovereignty". In Davis (ed) 2023, pp. 63–76. Davis, Stuart; Ness, Immanuel. "1: Introduction: Why Are Economic Sanctions a Form of War?". In Davis (ed) 2023, pp. 1–26. Karuka, Manu. "3: Hunger Politics: Sanctions as Siege Warfare". In Davis (ed) 2023, pp. 51–62. Ness, Immanuel. "6: Transnational Allies of Sanctions: NGO Human Rights Organizations' Role in Reinforcing Economic Oppression". In Davis (ed) 2023, pp. 91–104. Wilpert, Gregory. "16: The US War on Venezuela". In Davis (ed) 2023, pp. 273–289. Yaffe, Helen. "8: US Sanctions Cuba 'to Bring About Hunger, Desperation and the Overthrow of the Government'". In Davis (ed) 2023, pp. 129–147. Garlick, Jeremy (2024). Advantage China: Agent of Change in an Era of Global Disruption. Bloomsbury Academic. ISBN 978-1-350-25231-8.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.